The general objective of this study is to evaluate the behavioral and molecular effects that the treatment with a specific SIRT2 inhibitor, the compound 33i, has in a transgenic mouse model of AD, the APP/PS1 model, both at central and peripheral levels. The gene discussed is APP; the disease is Alzheimer disease.